Mendeley出力
＜学術雑誌論文＞
Time-variant tumor growth trajectory models for in silico randomized controlled trials for patients with early-stage non-small cell lung cancer in optimizing stereotactic body radiation therapy
| 作成者 | |
|---|---|
| 本文言語 | |
| 出版者 | |
| 発行日 | |
| 収録物名 | |
| 巻 | |
| 号 | |
| 開始ページ | |
| 終了ページ | |
| 出版タイプ | |
| アクセス権 | |
| 利用開始日 | |
| 権利関係 | |
| 関連DOI | |
| 関連HDL | |
| 概要 | Purpose: Applying new treatments to real patients to verify therapeutic efficacy may induce various risks, such as critical adverse events. Additionally, there are ethical and financial issues in real...-world randomized controlled trials (RCTs). This study aimed to develop mathematical models of time-variant tumor growth trajectories (TGTs) for in silico RCTs targeting patients with stage I non-small cell lung cancer (NSCLC) to optimize stereotactic body radiation therapy (SBRT). Methods: The basic idea of the in silico RCT was to evaluate the endpoint of progression-free survival (PFS) curves for the two regimens derived from TGTs for virtual patient data produced via mathematical models. TGT models with a relative number of tumor cells were proposed by integrating the Bertalanffy-Pütter (BP) model and linear quadratic model into tumor growth models. To validate the proposed models, we performed three RCTs, 30 Gy/1 fraction (Fr) versus 60 Gy/3 Fr, 48 Gy/4 Fr versus 75 Gy/25 Fr, and 34 Gy/1 Fr versus 48 Gy/4 Fr. Results: The three in silico RCTs showed no statistically significant differences in PFS curves, which was similar to the results of three previous studies. Conclusions: The proposed mathematical models could be leveraged for in silico RCTs to optimize SBRT.続きを見る |
本文ファイル
| ファイル | ファイルタイプ | サイズ | 閲覧回数 | 説明 |
|---|---|---|---|---|
| 公開年月日：2026.08.05 | 2.75 MB |
詳細
| PISSN | |
|---|---|
| EISSN | |
| レコードID | |
| 主題 | |
| タイプ | |
| 助成情報 | |
| 登録日 | 2025.11.18 |
| 更新日 | 2025.11.19 |